ConductScience.org, home

Paper34066940

Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review.

Fajardo-Orduña GR and 5 others. Int J Mol Sci, 2021. Cited by 37 papers, by iCite.

Cite this record

ConductScience Library. Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review. Papers, record 34066940. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34066940

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2021
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
37
iCite
Relative citation ratio, by iCite
2.56
iCite
Revised in PubMed
2021-06-16
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fajardo-Orduña GRGuadalupe Rosariohttps://orcid.org/0000-0002-1001-4073
2Ledesma-Martínez EEdgar
3Aguiñiga-Sánchez IItzenhttps://orcid.org/0000-0003-1692-8287
4Mora-García MLMaría de Lourdes
5Weiss-Steider BBenny
6Santiago-Osorio EEdelmirohttps://orcid.org/0000-0002-4876-0688

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CytarabineMajor topic
Drug Resistance, MultipleMajor topic
Drug Resistance, NeoplasmMajor topic
Leukemia, Myeloid, AcuteMajor topic
Animals
Cell Death
Humans
Models, Biological

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
PAPIIT IN229820General Directorate of Academic Personnel Affairs, National Autonomous University of MexicoPubMed

Source PubMed

Download CSV of grants

References98

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130228301Stem cell fate in cancer growth, progression and therapy resistance.Nat Rev Cancer2018https://conductscience.org/library/papers/30228301PubMed
228123146
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.
Biosci Trends2017https://conductscience.org/library/papers/28123146PubMed
326265695Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation.Blood2015https://conductscience.org/library/papers/26265695PubMed
429164055microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview.Front Oncol2017https://conductscience.org/library/papers/29164055PubMed
527973410Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs.Int J Mol Sci2016https://conductscience.org/library/papers/27973410PubMed
628286924Treatment of Relapsed/Refractory Acute Myeloid Leukemia.Curr Treat Options Oncol2017https://conductscience.org/library/papers/28286924PubMed
732601974Treatment of Relapsed Acute Myeloid Leukemia.Curr Treat Options Oncol2020https://conductscience.org/library/papers/32601974PubMed
825744718CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity.Cancer Res2015https://conductscience.org/library/papers/25744718PubMed
922869556Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells.Mol Cancer Ther2012https://conductscience.org/library/papers/22869556PubMed
1017054996Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells.J Surg Res2006https://conductscience.org/library/papers/17054996PubMed
1125322685Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.Leukemia2015https://conductscience.org/library/papers/25322685PubMed
1232657052Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues.Stem Cells Transl Med2020https://conductscience.org/library/papers/32657052PubMed
1322850751Overcoming implementation challenges of personalized cancer therapy.Nat Rev Clin Oncol2012https://conductscience.org/library/papers/22850751PubMed
1419842938Genetic factors influencing cytarabine therapy.Pharmacogenomics2009https://conductscience.org/library/papers/19842938PubMed
1517975014CREB is a critical regulator of normal hematopoiesis and leukemogenesis.Blood2008https://conductscience.org/library/papers/17975014PubMed
1623676220Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1.Cell Cycle2013https://conductscience.org/library/papers/23676220PubMed
1724756163miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1.Int J Oncol2014https://conductscience.org/library/papers/24756163PubMed
1830420752Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia.Nat Med2018https://conductscience.org/library/papers/30420752PubMed
1922383795Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.Blood2012https://conductscience.org/library/papers/22383795PubMed
2023087055Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7).Cancer Res2012https://conductscience.org/library/papers/23087055PubMed

See all 98 referencesDownload CSV of references

Cited by27

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 37 citations.

PMIDTitleJournalYearIn PapersSource
42469871TRIM24 stabilizes the p110 CUX1 oncoprotein via USP10 to promote chemoresistance in acute myeloid leukemia.J Transl Med2026https://conductscience.org/library/papers/42469871PubMed
42310288Targeting STAT3-mediated lipid metabolism reprogramming overcomes chemoresistance in acute myeloid leukemia.Cell Death Dis2026https://conductscience.org/library/papers/42310288PubMed
42266667miR-2110 orchestrates ERK-ELK1 transcriptional repression to induce cell-cycle arrest and enhance cytarabine sensitivity in acute myeloid leukemia.Front Oncol2026https://conductscience.org/library/papers/42266667PubMed
42143046Multi-omics analysis reveals LARP1 as a key integrator of translation and metabolism in AML.Oncogenesis2026https://conductscience.org/library/papers/42143046PubMed
41912486Targeting LAPTM5 enhances AML sensitivity to cytarabine through autophagy inhibition.Cell Death Dis2026https://conductscience.org/library/papers/41912486PubMed
41748545RRM1 inhibition sensitizes lung adenocarcinoma to decitabine treatment.Cell Death Dis2026https://conductscience.org/library/papers/41748545PubMed
41471781Antileukemic Potential of Sodium Caseinate in Cytarabine-Resistant HL60-CR50 Human Leukemia Cells.Molecules2025https://conductscience.org/library/papers/41471781PubMed
41317290Therapeutic potential of metformin-based combination therapy in acute myeloid leukemia.Discov Oncol2025https://conductscience.org/library/papers/41317290PubMed
40806596Sodium Caseinate Induces Apoptosis in Cytarabine-Resistant AML by Modulating SIRT1 and Chemoresistance Genes, Alone or in Combination with Cytarabine or Daunorubicin.Int J Mol Sci2025https://conductscience.org/library/papers/40806596PubMed
40427634The Novel Imiqualine EAPB02303 Is a Potent Drug for Treating Acute Myeloid Leukemia.Biomolecules2025https://conductscience.org/library/papers/40427634PubMed
40275490ARF6 Promotes AML Progression via Activation of PI3K/AKT/mTOR Signaling.Cancer Med2025https://conductscience.org/library/papers/40275490PubMed
39767527Protective Effect of Silver Nanoparticles Against Cytosine Arabinoside Genotoxicity: An In Vivo Micronucleus Assay.Int J Environ Res Public Health2024https://conductscience.org/library/papers/39767527PubMed
39469152CSE1L Silencing Enhances Cytarabine-mediated Cytotoxicity in Acute Myeloid Leukemia.Indian J Hematol Blood Transfus2024https://conductscience.org/library/papers/39469152PubMed
39339789Antineoplastic Activity of Sodium Caseinate in a Cytarabine-Resistant Mouse Acute Myeloid Leukemia Cell Line.Nutrients2024https://conductscience.org/library/papers/39339789PubMed
39036603Unraveling the role of long non-coding RNAs in therapeutic resistance in acute myeloid leukemia: New prospects & challenges.Noncoding RNA Res2024https://conductscience.org/library/papers/39036603PubMed
38910243Silencing LINC00987 ameliorates adriamycin resistance of acute myeloid leukemia via miR-4458/HMGA2 axis.Biol Direct2024https://conductscience.org/library/papers/38910243PubMed
38892165The Antifungal Potential of Niclosamide and Structurally Related Salicylanilides.Int J Mol Sci2024https://conductscience.org/library/papers/38892165PubMed
38699598Pharmacological p38 MAPK inhibitor SB203580 enhances AML stem cell line KG1a chemosensitivity to daunorubicin by promoting late apoptosis, cell growth arrest in S-phase, and miR-328-3p upregulation.Saudi Pharm J2024https://conductscience.org/library/papers/38699598PubMed
37665348E2F1 rs3213150 polymorphism influences cytarabine sensitivity and prognosis in patients with acute myeloid leukemia.Ann Hematol2023https://conductscience.org/library/papers/37665348PubMed
37623484Effective Prognostic Model for Therapy Response Prediction in Acute Myeloid Leukemia Patients.J Pers Med2023https://conductscience.org/library/papers/37623484PubMed

See all 27 cited byDownload CSV of cited by

Genes80

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABCA424PubTator's text mininghttps://conductscience.org/library/genes/24NCBI Gene
ABCB15243PubTator's text mininghttps://conductscience.org/library/genes/5243NCBI Gene
ABCB610058PubTator's text mininghttps://conductscience.org/library/genes/10058NCBI Gene
ABCC1089845PubTator's text mininghttps://conductscience.org/library/genes/89845NCBI Gene
ABCC1185320PubTator's text mininghttps://conductscience.org/library/genes/85320NCBI Gene
ABCC410257PubTator's text mininghttps://conductscience.org/library/genes/10257NCBI Gene
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
ATP7A538PubTator's text mininghttps://conductscience.org/library/genes/538NCBI Gene
BCL2596PubTator's text mininghttps://conductscience.org/library/genes/596NCBI Gene
BCL2L1598PubTator's text mininghttps://conductscience.org/library/genes/598NCBI Gene
CBFB865PubTator's text mininghttps://conductscience.org/library/genes/865NCBI Gene
CCND1595PubTator's text mininghttps://conductscience.org/library/genes/595NCBI Gene
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920NCBI Gene
CDA978PubTator's text mininghttps://conductscience.org/library/genes/978NCBI Gene
CDK41019PubTator's text mininghttps://conductscience.org/library/genes/1019NCBI Gene
CDK61021PubTator's text mininghttps://conductscience.org/library/genes/1021NCBI Gene
CEBPA1050PubTator's text mininghttps://conductscience.org/library/genes/1050NCBI Gene
CHD41108PubTator's text mininghttps://conductscience.org/library/genes/1108NCBI Gene
CMPK2129607PubTator's text mininghttps://conductscience.org/library/genes/129607NCBI Gene
CREB11385PubTator's text mininghttps://conductscience.org/library/genes/1385NCBI Gene

See all 80 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34066940

GET https://conductscience.org/api/papers/v1/34066940/references?page=2